These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6891111)

  • 1. Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators.
    Kruithof EK; Ransijn A; Bachmann F
    Thromb Res; 1982 Oct; 28(2):251-60. PubMed ID: 6891111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin solubilizing properties of certain anionic and cationic detergents.
    Chakrabarty S
    Thromb Res; 1989 Aug; 55(4):511-9. PubMed ID: 2510356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the fibrinolytic system.
    Robison AK; Collen D
    Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
    Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R; Fears R; Smith RA
    Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the reactivities of human urokinase and the porcine tissue plasminogen activator.
    Thorsen S; Astrup T
    Haemostasis; 1976; 5(5):295-305. PubMed ID: 14058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
    Wijngaards G
    Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the influence of reactants and buffer environment on clot lysis induced by human plasminogen activators.
    Westlund LE; Andersson LO
    Thromb Res; 1985 Jan; 37(1):213-23. PubMed ID: 4039077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 17. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
    Ries M; Zenker M; Gaffney PJ
    Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological characterization of plasminogen activators in human mixed saliva.
    Kjaeldgaard A; Kjaeldgaard M
    Acta Physiol Scand; 1986 Mar; 126(3):443-7. PubMed ID: 3515850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human seminal fibrinolytic activity: specific determinations of tissue plasminogen activator and urokinase.
    Van Dreden P; Gonzalès J; Poirot C
    Andrologia; 1991; 23(1):29-33. PubMed ID: 1910268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.